In (Faint) Praise of Pharmaceutical Import Tariffs

This Viewpoint discusses the reasons that drug manufacturing is leaving the US; highlights the weaknesses of tariffs as currently implemented for bringing it back; and calls for the moderate implementation of tariffs as one component of industrial policy and the reinvestment of tariff revenues in pharmaceutical innovation.

Authors

Institutions

Publication Details

Journal
JAMA
Published
2025-08-11
DOI
https://doi.org/10.1001/jama.2025.12207
Primary Topic
Public Procurement and Policy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

In (Faint) Praise of Pharmaceutical Import Tariffs

James C. Robinson
JAMA
Public Procurement and Policy
article

In (Faint) Praise of Pharmaceutical Import Tariffs

James C. Robinson
article en

Abstract

This Viewpoint discusses the reasons that drug manufacturing is leaving the US; highlights the weaknesses of tariffs as currently implemented for bringing it back; and calls for the moderate implementation of tariffs as one component of industrial policy and the reinvestment of tariff revenues in pharmaceutical innovation.

JAMAVol. 334(10)
University of California, Berkeley (US)
Decent work and economic growth
Openalex Percentile: Top 70%
Public Procurement and Policy
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

In (Faint) Praise of Pharmaceutical Import Tariffs — James C. Robinson · JAMA (2025) | TGRS Research Map | TGRS